Treatment failures of cefotaxime and latamoxef in meningitis caused by Enterobacter and Serratia spp

J Antimicrob Chemother. 1987 Dec;20(6):903-11. doi: 10.1093/jac/20.6.903.

Abstract

Despite the apparent success of several new cephalosporins in the treatment of Gram-negative bacterial meningitis, four treatment failures with cefotaxime or latamoxef were encountered (two caused by Enterobacter and two by Serratia spp.) In-vitro parameters of susceptibility of these clinical isolates were compared with those of a meningeal Ent. cloacae isolate from a successfully treated patient. The MIC and MBC values, degrees of inoculum effect, and amounts of beta-lactamase produced correlated poorly with the observed clinical outcome. However, the extent to which an isolate was killed by the cephalosporin used for treatment, in a 6-h in-vitro incubation, showed good correlation. We suggest that such a test should be used to predict clinical outcome of therapy because the other parameters such as the MIC and MBC values are not sufficiently discriminatory.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Cefotaxime / therapeutic use*
  • Drug Resistance, Microbial
  • Enterobacter / enzymology
  • Enterobacteriaceae Infections / drug therapy*
  • Humans
  • Male
  • Meningitis / drug therapy*
  • Middle Aged
  • Moxalactam / therapeutic use*
  • Serratia
  • beta-Lactamases / biosynthesis

Substances

  • beta-Lactamases
  • Cefotaxime
  • Moxalactam